9 studies found for:    "methodist hospital" | Open Studies | "Lung Neoplasms" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
2 Not yet recruiting TAA-SPECIFIC CTLS FOR SOLID TUMORS (TACTASOM)
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastric Cancer;   Glioma/Medulloblastoma;   Head and Neck Cancer;   HCC;   Lung Cancer;   Melanoma;   Neuroblastoma;   Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc);   Pancreatic Cancer;   Prostate Cancer;   Renal Cell Carcinoma;   Thyroid Cancer
Intervention: Biological: TAA-Specific CTLs
3 Recruiting Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Drug: etoposide
4 Not yet recruiting A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy
Conditions: Lung Neoplasms;   Thoracic Neoplasms;   Neoplasms by Site;   Neoplasms;   Lung Diseases
Interventions: Device: MIMIG System;   Drug: Indocyanine Green (ICG)
5 Recruiting Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: crizotinib;   Radiation: intensity-modulated radiation therapy;   Radiation: 3-dimensional conformal radiation therapy;   Drug: cisplatin;   Drug: etoposide;   Drug: paclitaxel;   Drug: carboplatin;   Other: laboratory biomarker analysis
6 Recruiting Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Drug: pemetrexed disodium
7 Recruiting LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: LDK378;   Drug: pemetrexed;   Drug: docetaxel
8 Recruiting Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: pemetrexed disodium;   Drug: cisplatin;   Drug: cediranib maleate;   Other: placebo
9 Recruiting ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
Condition: Bone Metastases
Intervention: Device: ExAblate 2100

Indicates status has not been verified in more than two years